- DHR Health Brownsville’s Free Educational Seminars on Arthritis & Joint Replacement, Nov. 4th & Dec. 6th 03/11/2025 22:15 Mega Doctor News - Texas DHR Health Orthopedic Surgeon Dr. Zain Sayeed invites community members to attend free Arthritis and Joint Replacement Educational Seminars that will take place at 12:00 p.m. on November 4 and December 2, 2025, at the DHR Health Brownsville Hospital, …
- Fertility Issues Tied to Osteoporosis Risk Post-Menopause 03/11/2025 21:57 Medscape TOPLINE: Among women with natural menopause, the risk for osteoporosis was elevated in those with a history of infertility, recurrent miscarriages, stillbirth, or low parity. Age at menopause had minimal or no influence on these associations. METHODOLOGY: …
- Amgen sues Colorado over state’s first-in-the-nation price ceiling on arthritis drug Enbrel 03/11/2025 20:35 Journal Advocate - Colorado The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ceiling on one of its medications conflicted with federal law. The company sued last year after …
- A Case of Corneal Melting Associated with Topical Diclofenac After Phacovitrectomy for Macular Pucker in a Patient with Rheumatoid Arthritis 03/11/2025 19:12 Dove Medical Press Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently utilized during both the perioperative and postoperative phases to manage ocular inflammation and pain.1 Topical NSAIDs find extensive use in addressing post-operative inflammation …
- Roche's Gazyva breaks new ground in lupus 03/11/2025 17:40 pharmaphorum Already approved for lupus nephritis, Roche's Gazyva could be heading for broader use in the potentially life-threatening autoimmune disorder after clearing a phase 3 trial. The results of the ALLEGORY trial of Gazyva (obinutuzumab) suggest that the …
- Phase III data for Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus: Roche 03/11/2025 17:09 Medical Dialogues Basel: Roche has announced statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva/Gazyvaro (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary …
- Roche's Gazyva, on an autoimmune hot streak, looks to further its new foothold in lupus with phase 3 win 03/11/2025 16:58 Fierce Pharma Roche’s Gazyva is at it again. After an FDA nod in lupus nephritis marked a fresh chapter for the aging blood cancer blockbuster just two weeks ago, the drug is looking to solidify its position as a contender in the lupus treatment landscape with a …
- Roche’s Phase III trial of Gazyva/Gazyvaro for SLE meets primary endpoint 03/11/2025 15:52 Clinical Trials Arena Roche has reported that its Phase III ALLEGORY trial of Gazyva/Gazyvaro (obinutuzumab) in adult patients with systemic lupus erythematosus (SLE) has met its primary goal. ALLEGORY demonstrated that more subjects achieved a four-point improvement in SLE …
- GLP-1s for diabetes reduce rheumatoid arthritis, gout risk 03/11/2025 13:38 Healio News November 03, 2025 2 min read Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Use of GLP-1 …
- I reversed my osteoporosis with one hour of weight-lifting a week 03/11/2025 12:53 The i paper Experts warn women that being slim in midlife might seem healthy, but it can raise the risk of brittle bones - so weightlifting is essential When Linda Marshall was diagnosed with osteoporosis at 55, it came as a “huge shock”. A dance and pilates teacher …
